13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • Research home > Beat Cancer Project search > Evaluating the capacity and benefit of precision medicine strategies to account for inter-patient variability with anti-cancer drugs used for advanced cancers

    Evaluating the capacity and benefit of precision medicine strategies to account for inter-patient variability with anti-cancer drugs used for advanced cancers

    Dr Madele vanDyk
    • Donor Funding: $240,000
    • Cancer Type: All Cancers
    • Cancer Stage: Treatment
    • Funded in: 2020
    • Dr Madele vanDyk
      Flinders University

    Since the discovery kinase inhibitors (KIs), a class of targeted therapy against terminal cancers, progression free survival and overall survival has greatly improved. However, TKIs undergo complex metabolism via liver enzymes (CYP3A4), which is known for its substantial variability in activity. However, no marker to identify CYP3A4 activity in patients currently exists. Due to the wide inter-individual variability, KI concentrations have varied up to >10 fold. Despite knowing this, variability between patients are inadequately addressed and a 'one-size fits all' prescribing is used. This clinical issue is widely recognised but still we do not account for this variability, resulting in some patients experiencing therapeutic failure or toxicity because the dose is not enough or too much.


    Therapeutic drug monitoring (TDM) can address this, measuring drug concentrations and changing the dose until the patient's concentration is in the 'target concentration'. Based on my previous work I have shown that with the implementation of TDM, we can prolong progression free survival significantly and thus improve patient quality of life. I have also shown that patient characteristics can be used to account for this inter-individual variability. Therefore, this study will evaluate the capacity and benefit of TDM to optimise KI dosing and determine which patient characteristics can help to predict a better dose so that we can personalise treatment to each individual and maximising treatment and minimising side effects. Since the economic health benefit has never been evaluated, this study will the first to address this by performing a cost-benefit analysis



  • Apply for funding

    Apply for funding

    Find out more about applications for funding.

  • Cancer statistics

    Cancer statistics

    Access the latest cancer statistics for South Australia

  • Clinical trials

    Clinical trials

    Access the list of current clinical trials taking place in South Australia.